Results 1 to 10 of 10

Thread: Eusol and Kringle Pharma

  1. #1

    Eusol and Kringle Pharma

    To the best of my knowledge Eusol and Kriingle Pharma have not received much attention here -- would like to get your perspective on the advancements of these two companies; have you heard of them? Do you think it is promising? Any additional information available?

    Eusol -- they are already in phase III
    https://en.eusol-biotech.com.tw/service.php

    "ES135 is a recombinant human acidic fibroblast growth factor (rhFGF1) with 135 amino acids. With its effect to promote neurite outgrowth, ES135 can be applied to the medical use of repairing neuron function. The sequence of ES135 has been patented in Taiwan, EU, China and the United States. A multi-center, double blind, randomized, placebo control study as the pivotal Phase 3 clinical trial for spinal cord injury is on-going."

    Kringle Pharma -- completed phase I/II for acute SCI (hopefully it can be translated to chronic SCI)
    http://www.kringle-pharma.com/en/


    "Phase I/II study of recombinant human HGF, KP-100IT, for acute spinal cord injury was completed, and the clinical study report has been issued. The positive results of this study will be published later in a scientific journal and presented at academic conferences."
    "KP-100IT, recombinant human HGF for the treatment of acute spinal cord injury, was designated as an orphan drug in Japan as of September 12, 2019, with the approval of the Minister of Health, Labor and Welfare."


  2. #2
    Very interesting. I tried emailing the place in Taiwan and email was rejected. We may need more local people to help us find out more about them....

  3. #3
    Junior Member
    Join Date
    Feb 2015
    Location
    Taipei Taiwan
    Posts
    22
    The inventor of ES135 is Henrich Chen, he has been mentioned in CC forum many times.
    https://www.ym.edu.tw/phd/HCheng_new.htm


    For your reference:
    http://www.cpmda.org.tw/news_show_n1.php?news_id=8706

    ("雅祥" = Eusol, "華碩" = ASUS, yes, a notebook big manufacturer, "鄭宏志"= Henrich Chen. Sorry my poor English, Google translation please. )

    The effects of ES135..........,no comments.
    Last edited by Jyi; 11-29-2019 at 03:54 AM.

  4. #4
    Thanks, jyi! What is considered 'serious spinal cord injury'? I think they all are serious heh. Wouldn't it be a good idea to try drug on people who could respond better such as incomplete injuries? -Jan

  5. #5
    Junior Member
    Join Date
    Feb 2015
    Location
    Taipei Taiwan
    Posts
    22
    Quote Originally Posted by FellowHawkeye View Post
    Thanks, jyi! What is considered 'serious spinal cord injury'? I think they all are serious heh. Wouldn't it be a good idea to try drug on people who could respond better such as incomplete injuries? -Jan
    It's a machine translation error, 嚴重的脊髓損傷 'serious' should be corrected by 'severe'.

  6. #6
    Quote Originally Posted by Jyi View Post
    It's a machine translation error, 嚴重的脊髓損傷 'serious' should be corrected by 'severe'.
    Okay, then completely paralyzed...

  7. #7
    Senior Member lunasicc42's Avatar
    Join Date
    Oct 2004
    Location
    Lutz, Fl USA*********C456
    Posts
    2,392
    GRAMMY or jyi or anyone, everytime I see the eusol listing on the clinicaltrials website I see that it is in phase 3, so I assume they have at least decent phase 2 results, can anyone find them published anywhere?
    "That's not smog! It's SMUG!! " - randy marsh, southpark

    "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


    2010 SCINet Clinical Trial Support Squad Member
    Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

  8. #8
    Quote Originally Posted by lunasicc42 View Post
    GRAMMY or jyi or anyone, everytime I see the eusol listing on the clinicaltrials website I see that it is in phase 3, so I assume they have at least decent phase 2 results, can anyone find them published anywhere?
    This publication mentions the two acute treatments discussed in this thread. LINK (free access)

    Time is spine: a review of translational advances in spinal cord injury

    The one specific to Eusol Phase 3 is on page 9 in Table 3 (TABLE 3. Summary of active phase III RCTs for traumatic SCI) and discussion page 10.
    ES135/rhFGF1
    3 Active Centers in (Taiwan)
    Patient target: 100
    Age 18-65 yrs;
    AIS grade A
    Intervention: ES 135 administered intrathecally
    Control: Placebo administered intrathecally
    Primary Outcome: Change in ASIA motor score at 48 weeks

    ES135/rhFGF1

    Fibrin glue containing acidic fibroblast growth factor(aFGF) has been studied as a possible repair strategy for SCI. In animal studies, aFGF, in conjunction with a peripheral nerve graft, has demonstrated potential to support axonal regeneration and formation of white matter to gray matter connections.24,101 This was tested in a human for the first time in 2004.25 The patient was a young male with chronic paraplegia and a complete spinal cord gap resulting from a stabbing injury. The technique involved bridging the spinal cord gap with sural nerve grafts and applying fibrin glue mixed with aFGF to the grafted area.This patient improved from being wheelchair-bound to being able to ambulate independently with a walker. A phase I pilot study tested local application of fibrin glue with aFGF without nerve grafting in 9 patients with chronic SCI (> 5 months).180 The procedure was well tolerated,and the patients demonstrated significant improvement in ASIA motor and sensory scores. In a subsequent larger trial that involved 49 chronic SCI patients, application of aFGF with fibrin glue and duraplasty performed via laminectomy was combined with adjuvant booster treatment of combined aFGF and fibrin glue at 3 and 6 months post surgery via lumbar puncture.179 Again, the use of aFGF was found to be safe and feasible; significant improvements were seen in ASIA motor and sensory scale scores, AIS grade, neurological level, and Functional Independence Measure (FIM) score at 24 months after treatment. A phase III multi-center, double-blinded, placebo-controlled,randomized trial of aFGF (ES 135; EUSOL Biotech Co.,Ltd.) is currently enrolling patients (NCT03229031). Eligible patients are 18 to 65 years of age and have an AIS A SCI. The target enrollment is 100 patients. The primary outcome is change in ASIA motor score at 12 months.

    The Kringle Pharma: Table 2: Page 6. (TABLE 2. Summary of select, ongoing therapeutic phase I/II trials for traumatic SCI)

    KP-100IT (HGF)
    Kringle Pharma Inc.
    Subjects: 48
    Age 18-75 yrs;
    modified Frankel grade A,B1, or B2; neurological level below C3
    HGF intrathecal 0.6mg at 72 hrs; repeat wkly ?5
    Control: Placebo at 72 hrs;repeat wkly 5AEs over 24 wks;
    ASI A motor score at 24 wks
    P-100 concentration in plasma & CSF at 6 wks;
    ASIA motor score at 12 wks;
    ASI A sensory score at 24 wks; modified Frankel scale at 24 wks

    Hepatocyte Growth Factor Hepatocyte growth factor (HGF) is a c-Met receptor ligand that promotes angiogenesis, mitogenesis, and cell motility in the liver. In models of myocardial infarction and stroke, HGF has been shown to enhance angiogenesis and improve endogenous cell survival.84,85 In a preclinical study of SCI in non-human primates, intrathecal HGF was found to enhance ventral motor neuron survival, reduce cavitation at the injury epicenter, and improve motor outcomes.85 In a subsequent non-human primate study, HGF was shown to promote angiogenesis after cervical injury resulting in significant improvements in upper limb recovery.84 Kringle Pharma Inc. is now recruiting for a phase I/II placebo-controlled study (N = 48; NCT02193334) of KP-100IT (intrathecal HGF) in patients with modified Frankel scale A/B1/B2 cervical injuries within 72 hours of injury; 24-week follow-up results are expected in 2019.
    Last edited by GRAMMY; 12-08-2019 at 07:27 PM.

  9. #9
    Senior Member lunasicc42's Avatar
    Join Date
    Oct 2004
    Location
    Lutz, Fl USA*********C456
    Posts
    2,392
    But the current eusol trial is about chronically injured patients correct? I wish I could find the results from phase 2 of this: https://clinicaltrials.gov/ct2/show/...draw=2&rank=49
    "That's not smog! It's SMUG!! " - randy marsh, southpark

    "what???? , you don't 'all' wear a poop sac?.... DAMNIT BONNIE, YOU LIED TO ME ABOUT THE POOP SAC!!!! "


    2010 SCINet Clinical Trial Support Squad Member
    Please join me and donate a dollar a day at http://justadollarplease.org and copy and paste this message to the bottom of your signature

  10. #10
    Quote Originally Posted by lunasicc42 View Post
    But the current eusol trial is about chronically injured patients correct? I wish I could find the results from phase 2 of this: https://clinicaltrials.gov/ct2/show/...draw=2&rank=49
    A number of phase III randomized controlled trials(RCTs) testing the safety and efficacy of neuro-protectiveand regenerative therapies for acute traumatic SCI are currently underway (Table 3).


    In a subsequent larger trial that involved 49 chronic SCI patients, application of aFGF with fibrin glue and duraplasty performed via laminectomy was combined with adjuvant booster treatment of combined aFGF and fibrin glue at 3 and 6 months post surgery via lumbar puncture. (179) Again, the use of aFGF was found to be safe and feasible; significant improvements were seen in ASIA motor and sensory scale scores, AIS grade, neurological level, and Functional Independence Measure (FIM) score at 24 months after treatment.

    Reference (179) Wu JC, Huang WC, Chen YC, Tu TH, Tsai YA, Huang SF,et al:
    Acidic fibroblast growth factor for repair of humanspinal cord injury: a clinical trial.
    J Neurosurg Spine15:216–227, 2011 (60 patient trial and 49 patients completed the study)
    LINK

    Phase 1 LINK (9 patients)
    Last edited by GRAMMY; 12-08-2019 at 08:07 PM.

Similar Threads

  1. Lookout Big Pharma! The Mushrooms are on the way!
    By Oddity in forum Science, Medicine, & Technology
    Replies: 26
    Last Post: 12-22-2018, 07:18 PM
  2. StemCell Pharma, Inc.,
    By manouli in forum Cure
    Replies: 0
    Last Post: 03-08-2007, 03:38 PM
  3. GW Pharma rolls on
    By Max in forum Funding, Legislation, & Advocacy
    Replies: 0
    Last Post: 06-14-2002, 12:10 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •